{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:26:11Z","timestamp":1790108771132,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T00:00:00Z","timestamp":1745107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974005"],"award-info":[{"award-number":["81974005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-SYBLD2022MS-0055"],"award-info":[{"award-number":["Y-SYBLD2022MS-0055"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018806","name":"Department of Science and Technology of Hubei Province","doi-asserted-by":"publisher","award":["CXPJJH12000009\\u2013204"],"award-info":[{"award-number":["CXPJJH12000009\\u2013204"]}],"id":[{"id":"10.13039\/501100018806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2025AFD777"],"award-info":[{"award-number":["2025AFD777"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.intimp.2025.114695","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T07:46:45Z","timestamp":1745221605000},"page":"114695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Long-term outcomes in patients with persistent EBV-DNA positivity after primary Epstein-Barr virus infection and clinical implications of rituximab therapy"],"prefix":"10.1016","volume":"156","author":[{"given":"Min","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zetong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2025.114695_bb0005","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1128\/jvi.61.5.1416-1420.1987","article-title":"Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV\/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d","volume":"61","author":"Nemerow","year":"1987","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.intimp.2025.114695_bb0010","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00428-20","article-title":"CD21 (complement receptor 2) is the receptor for Epstein-Barr virus entry into T cells. Longnecker RM, editor","volume":"94","author":"Smith","year":"2020","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.intimp.2025.114695_bb0015","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.3390\/cancers12113202","article-title":"Chronic Active Epstein\u2013Barr Virus Infection: Is It Immunodeficiency, Malignancy, or Both?","volume":"12","author":"Fujiwara","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.intimp.2025.114695_bb0020","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12185-023-03660-5","article-title":"Updated guidelines for chronic active Epstein\u2013Barr virus disease","volume":"118","author":"Kawada","year":"2023","journal-title":"Int. J. Hematol."},{"issue":"21","key":"10.1016\/j.intimp.2025.114695_bb0025","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMcp1001116","article-title":"Infectious mononucleosis","volume":"362","author":"Luzuriaga","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"apr212","key":"10.1016\/j.intimp.2025.114695_bb0030","doi-asserted-by":"crossref","first-page":"h1825","DOI":"10.1136\/bmj.h1825","article-title":"Infectious mononucleosis","volume":"350","author":"Lennon","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.intimp.2025.114695_bb0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/1573396320666230801091558","article-title":"Infectious Mononucleosis: An Updated Review","volume":"20","author":"Leung","year":"2024","journal-title":"CPR"},{"issue":"7335","key":"10.1016\/j.intimp.2025.114695_bb0040","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"virus particles in cultured lymphoblasts from burkitt\u2019s lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.intimp.2025.114695_bb0045","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood.2019000568","article-title":"An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma","volume":"134","author":"Murray","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2025.114695_bb0050","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/1078-0432.CCR-0670-3","article-title":"Epstein-Barr virus and Cancer","volume":"10","author":"Thompson","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.114695_bb0055","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/aje\/kwu176","article-title":"Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature","volume":"180","author":"Coghill","year":"2014","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.intimp.2025.114695_bb0060","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1098\/rstb.2016.0271","article-title":"Epstein\u2013Barr virus-associated lymphomas","volume":"372","author":"Shannon-Lowe","year":"2017","journal-title":"Philos. Trans. R. Soc. B"},{"key":"10.1016\/j.intimp.2025.114695_bb0065","doi-asserted-by":"crossref","unstructured":"Bednarska K, Chowdhury R, Tobin JWD, et al. Epstein\u2013Barr virus-associated lymphomas decoded. Br. J. Haematol. 2024; 204(2):415\u2013433. https:\/\/doi.org\/10.1111\/bjh.19255.","DOI":"10.1111\/bjh.19255"},{"issue":"12","key":"10.1016\/j.intimp.2025.114695_bb0070","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein\u2013Barr virus: more than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.114695_bb0075","doi-asserted-by":"crossref","unstructured":"Vockerodt M, Yap L, Shannon-Lowe C, et al. The Epstein\u2013Barr virus and the pathogenesis of lymphoma. J. Pathol. 2015; 235(2):312\u2013322. https:\/\/doi.org\/10.1002\/path.4459.","DOI":"10.1002\/path.4459"},{"key":"10.1016\/j.intimp.2025.114695_bb0080","unstructured":"Bjornevik K, M\u00fcnz C, Cohen JI, Ascherio A. Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat. Rev. Neurol. 2023; 19(3):160\u2013171. https:\/\/www.nature.com\/articles\/s41582-023-00775-5."},{"issue":"6578","key":"10.1016\/j.intimp.2025.114695_bb0085","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.114695_bb0090","article-title":"Recent Advances in Diagnostic Approaches for Epstein\u2013Barr Virus","volume":"9(3):226","author":"Abusalah","year":"2020","journal-title":"Pathogens"},{"issue":"2","key":"10.1016\/j.intimp.2025.114695_bb0095","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.autrev.2011.08.005","article-title":"Autoimmune disease: a role for new anti-viral therapies?","volume":"11","author":"Dreyfus","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2025.114695_bb0100","article-title":"Epstein\u2013Barr virus-associated B-cell lymphoproliferative disorder meeting the definition of CAEBV B cell disease: a case report","volume":"23(1):453","author":"Ma","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.intimp.2025.114695_bb0105","article-title":"Virological Markers in Epstein\u2013Barr Virus-Associated Diseases","volume":"15(3):656","author":"Lupo","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2025.114695_bb0110","article-title":"Fluorescence in situ hybridization is superior for monitoring Epstein Barr viral load in infectious mononucleosis patients","volume":"17(1):323","author":"Cao","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.intimp.2025.114695_bb0115","unstructured":"Kimura H, Sofue A. Monitoring of cell-free viral DNA in primary Epstein-Barr virus infection."},{"issue":"47","key":"10.1016\/j.intimp.2025.114695_bb0120","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.intimp.2025.114695_bb0125","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1054\/bjoc.2001.2127","article-title":"Rituximab: mechanisms and applications","volume":"85","author":"Johnson","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2025.114695_bb0130","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692500685X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692500685X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:50:30Z","timestamp":1762552230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692500685X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":26,"alternative-id":["S156757692500685X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114695","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes in patients with persistent EBV-DNA positivity after primary Epstein-Barr virus infection and clinical implications of rituximab therapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114695"}}